Biomedica	Management Corporation
	Bright Minds at Work on unique coagulopathy-related technologies: Hemostatics for high volume hemorrhage, sepsis, and anti-ischemic resuscitation fluids			ClotFoam and the future of trauma and laparoscopic surgery Glyco 23 Cost-effective treatment for sepsis Neutrolide for resuscitation fluids
	Who we are			What we do
	Biomedica Management Corporation is a research and development company headquartered at the SUNY Downstate Biotech Center in Brooklyn, NY, with biochemistry labs at the UMBC TechCenter in Baltimore, MD. The company was formed in 1999 under an innovative business model that explores and develops critical technologies in collaboration with academic scientists. Biomedica develops critical, affordable and effective technologies-targeting prevalent conditions with the potential to lead in multimillion dollar markets. Management Team • CEO, George Falus PhD Founder of Biomedica and former Director of the Interamerican College of Physicians & Surgeons • CFO Jack Goldman CPA Joined Biomedica in 2007 when he retired as Auditor at Department of Defense • VP Marketing Warren Pearlson Former Program Manager at Zeneca and Pfizer • VP University and Government Relations, Stella Manne PhD joined Biomedica in 2009 from the City University of New York (CUNY) where she was was Deputy Director for the Centers of Advanced Technology in Photonics Applications. She previously served as Director of Technology Development and Industry Sponsored Research at New York Medical College. • VP Research Martin Bluth, MD PhD Before joining the company Dr. Bluth was Director of Research at SUNY Downstate and Director of Blood Center at Wayne State University			The company is developing a pipeline of novel therapeutic agents to control ischemia, sepsis, and hemostasis, with civilian and military applications. These technologies address serious unmet medical needs. Its leading product, ClotFoam, is a hemostatic sealant for use in non-compressible high-volume hemorrhage, with important applications in trauma, laparoscopic surgery and wound healing. Second in the pipeline is a glycolipid derivative (Glyco 23) for the treatment of sepsis, followed by a small-molecule selectin blocker with anti-ischemic properties (Neutrolide), for application in ischemic conditions such as transplantation and resuscitation. We generate therapies that are either not currently available, or that are highly differentiated from existing treatments. Our chemistry, surgical, clinical and biology teams and efforts are highly integrated, and are characterized by the rapid generation of relevant data. If we were to look two years into the future, we see over 60 percent of surgical procedures conducted with minimally-invasive laparoscopic techniques, using non-compressible hemostatic sealants such as ClotFoam; and a substantial improvement in life saving procedures following accidents and other traumatic events, including casualties in the battlefield. Three years from now, we expect to prevent or control the development of sepsis without antibiotics by drugs that are affordable and have no contraindications. At the same time we expect to be able to prevent ischemic damage during resuscitation in hypovolemic state.